Whitepapers
Pharma white papers on contemporary issues, technologies, research, etc. are presented in this section to enable the readers with rich information and knowledge. This section provides white papers related to all the spheres of the pharma industry.
Large Molecule Bioanalysis- Outsourcing opportunities & Challenges
Sarika Khasnis Research Analyst Beroe Inc Abstract The trade group Pharma for large pharmaceuticals has announced that industry has more than biologics under development having different therapeutic area focus The biologics market is estimated to be approximately billion by with a gr
Orphan Drugs – Sourcing API from Emerging Markets
Vaishnavi Loganathan Research Analyst Beroe Inc Abstract The drugs which are developed for the treatment of rare diseases diseases which affect a very small population are called Orphan Drugs The Governments of various countries provide incentives and patent exclusivities in order to encourage orpha
M&As in Health Economics and Outcome Research Sourcing Implications
Satyam Mishra Research Analyst Beroe Inc Abstract Health Economics and Outcome Research HEOR function has gained wide acceptance due to the regulatory authorities demanding more data for proving drug effectiveness and payers requiring data for reimbursement Lesser barriers to entry resulted in a fra
Anti-counterfeiting – Technology
Sarabjeet Singh Sharad Senior Research Analyst Beroe Inc International free trade and inadequate drug regulation have led to the expansion of trade in counterfeit drugs worldwide Almost of medicines representing close to billion globally are said to be illegal Around of products in the legal pharmaceutical supply chain in the developed world a
Pharma\'s New Worldview - Transforming R&D through Emerging Markets
To date research and development RD within the pharmaceutical industry has been dominated by a developedmarket perspective But as emerging markets change Pharmas worldview its time for drugmakers to fundamentally rethink how RD is done Over US billion worth of products will lose patent protection over the next decade And late stage failures and sa
Make your move: Taking Clinical Trials to the Best location
Should pharmaceutical companies augment their offshore strategies by performing some clinical trials in lowercost locations The short answer is yes Emerging markets offer faster time to market reduced costs and the same high quality that companies demand But which countries present the best opportunities China India and Russia top the list according to AT Kearneys Country Attractiveness Index for...
Better Wet Granulation: Development, Scale-up and Manufacture
By Tim Freeman Freeman Technology Wet granulation is a common unit operation in the pharmaceutical industry yet accurate endpoint detection remains a challenge Here we examine the contribution that dynamic powder rheometry can make highlighting its ability to detect the transition from wet mass to granulate with the required sensitivity Quantification of this transition point with a measure that...
Mobile Intelligence
Putting the power of your CRM solution at your fingertips Individuals in commercial teams within Life Sciences companies travel every day to build deeper relationships with their stakeholders across multiple locations in a given territory Successful Life Sciences companies focus on leveraging proven mobile devices to incr
One Key
Cegedim Relationship Management is pleased to update you on the progress of data optimization services in China With the release of the new healthcare reform plan in early April China is at a turning point After many years of unequal medical access for the countrys poor rural majority which resulted in outbreaks of social unrest in recent years the
Cegedim Relationship Management
During the last few years a shift has occurred within sales organizations in global pharmaceutical companies Instead of focusing all their sales representatives promotional efforts on individual prescribers the companies have become more interested in how they address key accounts such as managed care organizations government agencies institutions and longterm care facilities
